Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Dec 3.

Published in final edited form as: Mol Immunol. 2007 Feb 2;44(10):2598–2604. doi: 10.1016/j.molimm.2006.12.011

Fig. 5 — A) Western blot of serum samples from patients with IgAN and healthy controls developed with HAA after neuraminidase treatment on the membranes. Load of serum samples was normalized to IgA concentration of 0.25 μg/well for separation by SDS-PAGE under reducing conditions.

B) Western blot of purified IgA1 isolated from serum of an IgAN patient and digested with 3 different IgA proteases (1, Clostridium ramosum AK183; 2, Streptococcus pneumoniae TIGR 4; 3, Haemophilus influenzae HK50), desialylated and probed with HAA. The amino acid(s) with a Gal-deficient O-glycans was localized to a site between the cleavage sites 2 and 3.

Fig. 5 — A) Western blot of serum samples from patients with IgAN and healthy controls developed with HAA after neuraminidase treatment on the membranes. Load of serum samples was normalized to IgA concentration of 0.25 μg/well for separation by SDS-PAGE under reducing conditions.

B) Western blot of purified IgA1 isolated from serum of an IgAN patient and digested with 3 different IgA proteases (1, Clostridium ramosum AK183; 2, Streptococcus pneumoniae TIGR 4; 3, Haemophilus influenzae HK50), desialylated and probed with HAA. The amino acid(s) with a Gal-deficient O-glycans was localized to a site between the cleavage sites 2 and 3.